| Ratios |
|
|
| Net profit margin
| 5.57%
| 15.52%
|
| Operating margin
| 8.65%
| 20.81%
|
| EBITD margin
| -
| 23.85%
|
| Return on average assets
| -
| 12.44%
|
| Return on average equity
| -
| 36.70%
|
| Employees
| 6,944
| -
|
| Carbon Disclosure Rating
| -
|
-
|
|
|
|
| AUROPHARMA Company Summary |
| |
|
Aurobindo Pharma Limited (APL) is an integrated pharmaceutical company. The Company has a product portfolio of over 250 finished dosage formulations and 200 active pharmaceutical ingredients (APIs) with product portfolio in life-style disease, anti- acquired immunodeficiency syndrome (AIDS), anti-infectives and pain management with pediatric products and technologies. The Company?s subsidiaries include Milpharm Limited, Aurobindo Pharma Pty Ltd, APL Pharma Thai Limited, Aurobindo Pharma (Malta) Ltd, Agile Pharma (Malta) Ltd, Auropharma Inc., Aurobindo Pharma USA Inc., Cephazone Pharma LLC (JV), Aurobindo Pharma (Italia) S.r.l, Aurobindo Pharma France SARL, Aurobindo Pharma GmbH, SIA Aurobindo Baltics, Aurobindo Pharma Japan KK, APL IP company Ltd, Laboratorios Aurobindo S.L, Aurobindo Pharma (Aus) Pty Ltd, ALL Pharma (Shangai) Trading Co. Ltd, Helix healthcare B.V, Aurobindo Pharma productos Farmaceuticos LTDA and Aurobindo Pharma Industria Pharmaceutica LTDA.
|
|